Corbus Pharmaceuticals Holdings Stock Prediction and Forecast [CRBP]

AI-generated source summary

Corbus Pharmaceuticals Holdings, based on moving averages, presents a positive forecast. Short-term averages are above the long-term average. Downward corrections, support lies at $9.86 and $9.13. A breakdown of these values will issue sell signals. A buy signal from the 3-month Moving Average Convergence Divergence (MACD). Sell signal a pivot top on Wednesday, August 27, further fall is indicated until a new bottom pivot has been found. Volume fell along with the price, which is technically positive. CRBP stock has medium daily movements and medium risk. Short term: Buy long term: Sell. Trading levels with accumulated volume: Resistance at $10.47, Support at $8.67. Vitals : Risk is classified as medium and the weekly volatility is 6.84%. Insiders Buy 1938540 shares and sell 138404 shares. The analysis suggests a buy and expect CRBP to open higher by approximately $0.233 to start trading at $10.13.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   29 Aug 2025, 03:10 UTC

   The analyst published the original source item.

2. First prediction resolved

   02 Sept 2025, 13:30 UTC

   The first evaluable outcome in this case reached a terminal result.

3. Case evaluation completed

   02 Sept 2025, 13:30 UTC

   All evaluable predictions in this case reached terminal outcomes.

4. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

5. Market predictions extracted

   18 May 2026, 20:47 UTC

   1 eligible signal linked to this case.

6. Outcome tracking started

   02 Jul 2026, 01:22 UTC

   Tahlil Plus began monitoring the extracted predictions.